arrow_back Back Filing freshness 10-K FY 2026 SEC EDGAR

download Export Data

Grace Therapeutics, Inc.

GRCE

$2.15 ▲ +0.01 (+0.47%) at close

9 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Bearish

auto_awesome

Analytical Summary

Grace Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $35.5M

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -14.2% ↗

FCF / Share $-0.54 ↗

Trailing P/E —

Price / Book 0.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$100.00M

↑ +50920.4% —

Net Income Profit after all expenses

$-7.79M

↑ +18.6% —

FCF / Share Free cash flow per share

$-0.54

↑ +56.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2026 Mar 31, 2026 10-K ↗	FY 2025 Mar 31, 2025 10-K ↗	FY 2024 Mar 31, 2024 10-K ↗	FY 2023 Mar 31, 2023 10-K ↗	FY 2022 Mar 31, 2022 10-K ↗	FY 2021 Mar 31, 2021 10-K ↗	FY 2020 Mar 31, 2020 10-K ↗	FY 2019 Mar 31, 2019 10-K ↗	FY 2018 Mar 31, 2018 10-K ↗
Revenue Growth YoY (%)	—	—	—	—	50920.4% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+636405%)	—	—	—	—
EPS Growth YoY (%)	40.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	41.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	76.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-2014.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	18.6% Good ↑ Good Improving Year-over-year change in net income	25.6% Excellent ↑ Excellent Improving Year-over-year change in net income	69.7% Excellent ↑ Excellent Improving Year-over-year change in net income	-332.1% Weak ↓ Weak Declining Year-over-year change in net income	50.1% Excellent ↑ Excellent Improving Year-over-year change in net income	22.9% Good Good Year-over-year change in net income	35.2% Excellent Excellent Year-over-year change in net income	—	—
FCF Growth YoY (%)	56.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	4.7% Caution ↑ Caution Improving Year-over-year change in free cash flow	39.5% Excellent Excellent Year-over-year change in free cash flow	-357.5% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2026 Mar 31, 2026 10-K ↗	FY 2025 Mar 31, 2025 10-K ↗	FY 2024 Mar 31, 2024 10-K ↗	FY 2023 Mar 31, 2023 10-K ↗	FY 2022 Mar 31, 2022 10-K ↗	FY 2021 Mar 31, 2021 10-K ↗	FY 2020 Mar 31, 2020 10-K ↗	FY 2019 Mar 31, 2019 10-K ↗	FY 2018 Mar 31, 2018 10-K ↗
Operating Margin (%) (%)	—	—	—	—	-15.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-204%)	—	—	—	—
Effective Tax Rate (%) (%)	17.9% Good → Good Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	25.1% Caution ↑ Caution Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	12.5% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	18.4% Good ↑ Good Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	6.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	—	—	—	-9.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-182%)	—	—	—	—
FCF Margin (%) (%)	—	—	—	—	-17.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	1.14x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.56x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.38x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.76x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2026 Mar 31, 2026 10-K ↗	FY 2025 Mar 31, 2025 10-K ↗	FY 2024 Mar 31, 2024 10-K ↗	FY 2023 Mar 31, 2023 10-K ↗	FY 2022 Mar 31, 2022 10-K ↗	FY 2021 Mar 31, 2021 10-K ↗	FY 2020 Mar 31, 2020 10-K ↗	FY 2019 Mar 31, 2019 10-K ↗	FY 2018 Mar 31, 2018 10-K ↗
Return on Invested Capital (%)	-14.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-18.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-18.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-62.7% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-13.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-29.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-148.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-311.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-16.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-23.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-17.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-65.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-12.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-26.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-106.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-93.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-12.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-181%)	-14.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-196%)	-20.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-239%)	-62.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-516%)	-9.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-160%)	-35.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-336%)	-196.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1409%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2026 Mar 31, 2026 10-K ↗	FY 2025 Mar 31, 2025 10-K ↗	FY 2024 Mar 31, 2024 10-K ↗	FY 2023 Mar 31, 2023 10-K ↗	FY 2022 Mar 31, 2022 10-K ↗	FY 2021 Mar 31, 2021 10-K ↗	FY 2020 Mar 31, 2020 10-K ↗	FY 2019 Mar 31, 2019 10-K ↗	FY 2018 Mar 31, 2018 10-K ↗
Net Debt (USD)	$-16.98M	$-22.13M	$-23.00M	$-27.88M	$-30.34M	$-50.94M	$-14.24M	$-6.42M	—

📊 What does each share earn? 6 metrics

Metric	FY 2026 Mar 31, 2026 10-K ↗	FY 2025 Mar 31, 2025 10-K ↗	FY 2024 Mar 31, 2024 10-K ↗	FY 2023 Mar 31, 2023 10-K ↗	FY 2022 Mar 31, 2022 10-K ↗	FY 2021 Mar 31, 2021 10-K ↗	FY 2020 Mar 31, 2020 10-K ↗	FY 2019 Mar 31, 2019 10-K ↗	FY 2018 Mar 31, 2018 10-K ↗
Revenue per Share (USD)	—	—	—	—	$2.71	—	—	—	—
Basic EPS, GAAP (USD)	$-0.47	$-0.79	$-1.35	$-5.71	$-0.27	—	—	—	—
Free Cash Flow per Share (USD)	$-0.54	$-1.23	$-1.29	$-2.14	$-0.47	—	—	—	—
Book Value per Share (USD)	$3.87	$5.51	$6.57	$9.14	$2.44	—	—	—	—
Tangible Book Value per Share (USD)	$0.89	$1.43	$1.33	$2.51	$0.58	—	—	—	—
Basic Weighted Avg Shares (shares)	16.51M	12.09M	9.53M	7.44M	36.84M	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2026 Mar 31, 2026 10-K ↗	FY 2025 Mar 31, 2025 10-K ↗	FY 2024 Mar 31, 2024 10-K ↗	FY 2023 Mar 31, 2023 10-K ↗	FY 2022 Mar 31, 2022 10-K ↗	FY 2021 Mar 31, 2021 10-K ↗	FY 2020 Mar 31, 2020 10-K ↗	FY 2019 Mar 31, 2019 10-K ↗	FY 2018 Mar 31, 2018 10-K ↗
Working Capital (USD)	$15.23M	$20.78M	$22.33M	$25.88M	$42.02M	$60.79M	$11.07M	$14.30M	—
Total Equity (USD)	$63.90M	$66.61M	$61.74M	$67.95M	$108.27M	$55.66M	$12.99M	$11.04M	$7.19M

📋 What is driving earnings? 4 metrics

Metric	FY 2026 Mar 31, 2026 10-K ↗	FY 2025 Mar 31, 2025 10-K ↗	FY 2024 Mar 31, 2024 10-K ↗	FY 2023 Mar 31, 2023 10-K ↗	FY 2022 Mar 31, 2022 10-K ↗	FY 2021 Mar 31, 2021 10-K ↗	FY 2020 Mar 31, 2020 10-K ↗	FY 2019 Mar 31, 2019 10-K ↗	FY 2018 Mar 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	$100.00M	$196.00K	—	—	—
Depreciation Expense (USD)	$7.00K	$7.00K	$11.00K	$124.00K	$0.00	$143.00K	$410.00K	$384.00K	—
Net Income, GAAP (USD)	$-7.79M	$-9.57M	$-12.85M	$-42.43M	$-9.82M	$-19.68M	$-25.51M	$-39.37M	—
Operating Cash Flow (USD)	$-8.87M	$-14.90M	$-12.33M	$-15.91M	$-17.23M	$-14.32M	$-22.95M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 30 quarters

Grace Therapeutics, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare GRCE with peers